References from scientific journals

Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.

Venter WDF, Sokhela S, Simmons B, Moorhouse M, Fairlie L, Mashabane N, Serenata C, Akpomiemie G, Masenya M, Qavi A, Chandiwana N, McCann K, Norris S, Chersich M, Maartens G, Lalla-Edward S, Vos A, Clayden P, Abrams E, Arulappan N, Hill A. Venter WDF, et al. Lancet HIV. 2020 Oct;7(10):e666-e676. doi: 10.1016/S2352-3018(20)30241-1. Lancet HIV. 2020. PMID: 33010240 Clinical Trial.

BACKGROUND: ADVANCE compared the efficacy and safety of two antiretroviral first-line combinations (dolutegravir combined with emtricitabine and either tenofovir disoproxil fumarate or tenofovir alafenamide), with a third regimen (efav …
BACKGROUND: ADVANCE compared the efficacy and safety of two antiretroviral first-line combinations (dolutegravir combined with emt …

HIV Preexposure Prophylaxis: A Review.

Riddell J 4th, Amico KR, Mayer KH. Riddell J 4th, et al. JAMA. 2018 Mar 27;319(12):1261-1268. doi: 10.1001/jama.2018.1917. JAMA. 2018. PMID: 29584848 Review.

IMPORTANCE: About 40 000 Americans and 2 million people worldwide are newly infected with HIV each year. The combination antiretroviral regimen, tenofovir disoproxil fumarate (TDF)/emtricitabine, taken as a single pill once daily, has been shown …
IMPORTANCE: About 40 000 Americans and 2 million people worldwide are newly infected with HIV each year. The combination antiretrovir …

Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.

Mayer KH, Molina JM, Thompson MA, Anderson PL, Mounzer KC, De Wet JJ, DeJesus E, Jessen H, Grant RM, Ruane PJ, Wong P, Ebrahimi R, Zhong L, Mathias A, Callebaut C, Collins SE, Das M, McCallister S, Brainard DM, Brinson C, Clarke A, Coll P, Post FA, Hare CB. Mayer KH, et al. Lancet. 2020 Jul 25;396(10246):239-254. doi: 10.1016/S0140-6736(20)31065-5. Lancet. 2020. PMID: 32711800 Clinical Trial.

Emtricitabine and tenofovir alafenamide was superior to emtricitabine and tenofovir disoproxil fumarate in all six prespecified bone mineral density and renal biomarker safety endpoints. ...Emtricitabine and tenofovir alafen …
Emtricitabine and tenofovir alafenamide was superior to emtricitabine and tenofovir disoproxil fumarat …

Drug Resistance During HIV Pre-Exposure Prophylaxis.

Gibas KM, van den Berg P, Powell VE, Krakower DS. Gibas KM, et al. Drugs. 2019 Apr;79(6):609-619. doi: 10.1007/s40265-019-01108-x. Drugs. 2019. PMID: 30963509 Free PMC article. Review.

Clinical studies have demonstrated that use of tenofovir disoproxil fumarate with or without emtricitabine as antiretroviral pre-exposure prophylaxis (PrEP) can decrease the risk of human immunodeficiency virus (HIV) acquisition when medication adheren …
Clinical studies have demonstrated that use of tenofovir disoproxil fumarate with or without emtricitabine as an …

Pre-exposure prophylaxis 2.0: new drugs and technologies in the pipeline.

Coelho LE, Torres TS, Veloso VG, Landovitz RJ, Grinsztejn B. Coelho LE, et al. Lancet HIV. 2019 Nov;6(11):e788-e799. doi: 10.1016/S2352-3018(19)30238-3. Epub 2019 Sep 23. Lancet HIV. 2019. PMID: 31558423 Review.

Pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate and emtricitabine was adopted by WHO as a strategy to reduce HIV incidence. Although shown to be highly effective in reducing HIV acquisition, the protective efficacy of oral tenofov …
Pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate and emtricitabine was adopted by WHO as a str …

Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF).

De Clercq E. De Clercq E. Biochem Pharmacol. 2016 Nov 1;119:1-7. doi: 10.1016/j.bcp.2016.04.015. Epub 2016 Apr 29. Biochem Pharmacol. 2016. PMID: 27133890 Review.

Tenofovir alafenamide (TAF) can be considered a new prodrug of tenofovir (TFV), as successor of tenofovir disoproxil fumarate (TDF). ...STR combinations containing TAF and emtricitabine could be paired with a range of third agents, …
Tenofovir alafenamide (TAF) can be considered a new prodrug of tenofovir (TFV), as successor of tenofovir disoproxil …

Efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Atripla): a review of its use in the management of HIV infection.

Deeks ED, Perry CM. Deeks ED, et al. Drugs. 2010 Dec 3;70(17):2315-38. doi: 10.2165/11203800-000000000-00000. Drugs. 2010. PMID: 21080746 Review.

The non-nucleoside reverse transcriptase inhibitor, efavirenz, and the two nucleoside reverse transcriptase inhibitors, emtricitabine and tenofovir disoproxil fumarate (tenofovir DF) are now available as a single-tablet regimen (efavir …
The non-nucleoside reverse transcriptase inhibitor, efavirenz, and the two nucleoside reverse transcriptase inhibitors, emtricitab …

Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns.

Tetteh RA, Yankey BA, Nartey ET, Lartey M, Leufkens HG, Dodoo AN. Tetteh RA, et al. Drug Saf. 2017 Apr;40(4):273-283. doi: 10.1007/s40264-017-0505-6. Drug Saf. 2017. PMID: 28130774 Free PMC article. Review.

We performed a literature search on PrEP in PubMed, global advocacy for HIV prevention (Aids Vaccine Advocacy Coalition) database, clinical trials registry " http://www.clinicaltrials.gov " and scholar.google, using combination search terms 'pre-exposure prophylaxis', 'saf …
We performed a literature search on PrEP in PubMed, global advocacy for HIV prevention (Aids Vaccine Advocacy Coalition) database, clinical …

Primary HIV-1 infection in users of pre-exposure prophylaxis.

Ambrosioni J, Petit E, Liegeon G, Laguno M, Miró JM. Ambrosioni J, et al. Lancet HIV. 2021 Mar;8(3):e166-e174. doi: 10.1016/S2352-3018(20)30271-X. Epub 2020 Dec 11. Lancet HIV. 2021. PMID: 33316212 Review.

However, primary HIV infection while using PrEP can occur, albeit rarely, and HIV drug resistance might develop. Furthermore, the scope of PrEP is expected to expand, and clinicians might face potential seroconversions and primary HIV infection in patients starting or taki …
However, primary HIV infection while using PrEP can occur, albeit rarely, and HIV drug resistance might develop. Furthermore, the sco …

Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority Trial.

Orkin C, Squires KE, Molina JM, Sax PE, Sussmann O, Lin G, Kumar S, Hanna GJ, Hwang C, Martin E, Teppler H. Orkin C, et al. Clin Infect Dis. 2021 Jul 1;73(1):33-42. doi: 10.1093/cid/ciaa822. Clin Infect Dis. 2021. PMID: 33336698 Free PMC article. Clinical Trial.

Participants were randomized to a daily fixed-dose tablet of DOR (100 mg), lamivudine (3TC; 300 mg) and tenofovir disoproxil fumarate (TDF; 300 mg) (DOR/3TC/TDF) or EFV (600 mg), emtricitabine (FTC; 200 mg) and TDF (300 mg) (EFV/FTC/TDF). The efficacy …
Participants were randomized to a daily fixed-dose tablet of DOR (100 mg), lamivudine (3TC; 300 mg) and tenofovir disoproxil …